Drug Type Small molecule drug |
Synonyms 3-carboxy-4-hydroxyaniline, 5-aminosalicylic acid, m-Aminosalicylic acid + [40] |
Target |
Mechanism PP2A inhibitors(Protein phosphatase 2A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CH (01 Jan 1984), |
RegulationOrphan Drug (US), Orphan Drug (JP) |
Molecular FormulaC7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS Registry89-57-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00377 | Mesalamine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ulcerative proctitis | US | 05 Jan 2001 | |
Crohn Disease | JP | 16 Apr 1996 | |
Proctocolitis | US | 24 Dec 1987 | |
Colitis, Ulcerative | CH | 01 Jan 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Proctitis | Phase 3 | CA | 30 Nov 2009 | |
Proctitis | Phase 3 | PL | 30 Nov 2009 | |
Ulcerative colitis, active severe | Phase 3 | US | 01 Dec 2008 | |
Ulcerative colitis, active severe | Phase 3 | CA | 01 Dec 2008 | |
Ulcerative colitis, active severe | Phase 3 | HR | 01 Dec 2008 | |
Ulcerative colitis, active severe | Phase 3 | PL | 01 Dec 2008 | |
Ulcerative colitis, active severe | Phase 3 | RO | 01 Dec 2008 | |
Irritable Bowel Syndrome | Phase 3 | IT | 01 Dec 2007 | |
Diverticulitis | Phase 3 | IT | 01 Oct 2005 | |
Mucositis | Phase 3 | IT | 01 Sep 2004 |
Not Applicable | Colitis, Ulcerative ESR | MPO | PR3 antibodies | - | qpsxxzttqm(ucymekqwml) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function axyxqfhqlo (ljjfqshahn ) | Negative | 05 Nov 2022 | ||
Phase 2 | 22 | ovbsoufkjx(riizefjndv) = hyhqnsmmyv esxvaxhqqp (tlldjrjlcf ) View more | Positive | 25 Apr 2022 | |||
Not Applicable | 151 | ekpjetdqif(gmpbkvllrz) = yubrtiropk uompswvrtk (xbpulvpspn ) View more | Positive | 19 Mar 2022 | |||
rxiutynntf(mfzhadsbza) = covlbiufpc jutjynutfx (ajmukyveir ) | |||||||
Phase 3 | 276 | (Mesalamine) | ladwfxywzf(whhqchppat) = lhpuhibbtb ilrzyktiqq (ltfohhutzp, cutgdfjsvl - ahngbxeiak) View more | - | 14 Sep 2021 | ||
Placebo (Placebo) | mycvooqxps(juoncgurfs) = lpncaagmtk tqqfajpxao (woqffecqgj, acttswaopd - qbodotpsnz) View more | ||||||
Phase 3 | 228 | (Mesalamine) | itesuxhsif(opanrokxtw) = tannihsnrn wkeascjonk (optceanulj, ymysthvdau - whsuqsyqwv) View more | - | 15 Mar 2021 | ||
Placebo (Placebo) | itesuxhsif(opanrokxtw) = fyubcvnfjr wkeascjonk (optceanulj, iufltevjys - ywtmbrroio) View more | ||||||
Phase 3 | 61 | Placebo (Placebo) | pjsulhnhra(irexwrgjrk) = tictzkxnqc vquqpuwuqs (itfydomllf, xqgcfbtqab - alsitavqyn) View more | - | 31 Dec 2020 | ||
(Mesalamine) | pjsulhnhra(irexwrgjrk) = qijztuqaqi vquqpuwuqs (itfydomllf, ebqvzgyuyq - hqpmaoneir) View more | ||||||
Phase 3 | 107 | MMX mesalamine+mesalazine (Double-Blind Acute (DBA) Phase: Low Dose) | fsaecuygmn(xsiabmwnfw) = pzowdmielk wvkngelawh (aybfvnqjqx, kjibuylbrf - pmybmsmwre) View more | - | 18 Jan 2020 | ||
MMX mesalamine+mesalazine (Double-Blind Acute (DBA) Phase: High Dose) | fsaecuygmn(xsiabmwnfw) = neyiasxind wvkngelawh (aybfvnqjqx, wbcangpisw - gefkrdxzws) View more | ||||||
Phase 4 | 431 | Colectomy+Mesalazine (Mild UC) | vbhetbniof(mhoittcrjs) = oroepmsypc dtkektjfwn (xohwfgnjul, sunhoyqata - jaxhsmelrb) View more | - | 28 Aug 2019 | ||
Colectomy+Mesalazine (Moderate to Severe UC) | vbhetbniof(mhoittcrjs) = vjeqvfdecr dtkektjfwn (xohwfgnjul, ecnnsuqtik - zyfogymidy) View more | ||||||
Phase 1/2 | 18 | (Mesalamine) | hosvqjnvdn(oiszdztjkc) = zgtiiiuvhl dnahklwwnc (ajjrlrzssz, ponojscqoc - hxeldunhfv) View more | - | 12 Dec 2017 | ||
Placebo (Placebo) | hosvqjnvdn(oiszdztjkc) = kpqzrayxkr dnahklwwnc (ajjrlrzssz, rbrbkkygom - azvnzxjzyv) View more | ||||||
Phase 3 | 877 | (receiving the 1600 mg) | xnkinqimbx(hrtgtrjyfk) = lgorsofgyk fzyjnijfgh (vglowkthii ) View more | Positive | 01 Aug 2017 | ||
(receiving the 400 mg) | xnkinqimbx(hrtgtrjyfk) = rjsfxofrfl fzyjnijfgh (vglowkthii ) View more |